Kashiv BioSciences & JAMP Pharma Launch Biosimilars in Canada

Kashiv BioSciences commercially launched Pexegra, a biosimilar referencing Neulasta, and Filra, a biosimilar referencing Neupogen, in the Canadian market. 

Pexegra and Filra biosimilars will be marketed in Canada through an exclusive agreement with JAMP Pharma Corporation.

Exegra (6 mg/0.6 mL pre-filled syringe) and Filra (300 mcg/0.5 mL and 480 mcg/0.8 mL pre-filled syringe) are used to treat neutropenia, low neutrophils, which are a type of white blood cell that fight infection, which is commonly experienced by patients undergoing chemotherapy. 

Sandeep Athalye, Chief Executive Officer of Kashiv Biosciences, said, “We are delighted to bring Pexegra and Filra to patients in Canada. Kashiv’s facilities are fully prepared to support JAMP’s commercialization efforts, and we look forward to working together to expand access to high-quality, affordable biosimilars worldwide.”